UiPath's profit turn is real, but the ARR guide still leaves the rebound a no-trade

Run timestamp: 2026-09-06 17:33 SGT Scope: U.S. market, long only Classification: No-trade screen, Reject for current execution Primary instrument: UiPath Class A common stock, NYSE, unlevered only if every execution gate later passes

Summary: UiPath fell 16.68% to $15.19 on September 4 even though fiscal Q2 revenue rose 13%, ARR rose 12%, GAAP operating income reached $32 million, and management raised its full-year revenue outlook. The price is disagreeing with the quarter because Q3 revenue guidance implies a marked slowdown and net new ARR was only $37 million. The cash bridge also improved less than the income statement: Q2 operating cash flow and company-defined adjusted free cash flow were each $31 million, while cash and marketable securities fell to $1.405 billion.

The reference-only map is $21.00/$17.50/$12.50 at 25%/50%/25%. The $17.50 base offers 15.21%, but the $12.50 bottom loses 17.71%, leaving a 0.86:1 gross reward-to-adverse-risk ratio. UiPath is useful rebound research, not a trade-qualified long.

Opportunity Ranking

The screen used three distinct mechanism searches:

automation ARR net new ARR guidance cash conversion stock compensation leadership change September 2026

title insurance selloff investment income claims reserve buyback cash September 2026

consumer apparel guidance cut inventory tariff cash debt September 2026 long rebound

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	UiPath (PATH)	Long	A 16.7% fall meets 13% revenue growth, 12% ARR growth, GAAP profit, and higher full-year guidance	Sep. 3 result and SEC exhibit; Sep. 4 tape	Q3 FY27 guide conversion and next filed cash bridge	104.58M event-day shares; direct short, options, dealer, and fund-flow evidence missing	Base +15.21%, adverse -17.71%, ratio 0.86:1, Reject	NYSE liquidity context, but current book and exit quality unavailable	Q3 growth slowdown, lower net new ARR, and AI commoditization
2	First American Financial (FAF)	Long	A 4.9% Friday fall may overstate rate sensitivity, but no same-day issuer catalyst was verified	Latest quote plus older operating evidence	Next quarterly title-order, claims, and investment-income update	Event volume 1.22M; direct positioning incomplete	No evidence-backed near-term +10% base case; Reject	NYSE listing; current spread and depth unavailable	Housing turnover, reserve development, and rate volatility
3	Oxford Industries (OXM)	Long	A severe retail reset can attract mean reversion, but the fresh guidance cut is operating evidence against the long	Sep. 4 market reaction and secondary result coverage	Next quarter and inventory clearance	Current direct positioning unavailable	Credible adverse path exceeds 5%; Reject	Small-cap retail gap and exit risk	Direct-to-consumer weakness, inventory, promotions, and guide cuts

Selected opportunity: PATH, long research only. Why this one now: It has the freshest primary operating evidence, the largest clean event tape, and a measurable conflict between current profitability and forward growth expectations. What should surprise the reader: The 16.7% selloff does not make the stock automatically cheap. Q3 revenue guidance around $442.5 million implies only about 8% year-over-year growth, so the market is testing reacceleration, not denying Q2 profitability.

Why This Is the Best Opportunity Right Now

UiPath's Q2 fiscal 2027 release reported $410.3 million of revenue, $1.938 billion of ARR, 109% dollar-based net retention, $32 million of GAAP operating income, and $89 million of non-GAAP operating income. Stock compensation fell to $45.0 million from $78.0 million.

Management guided Q3 revenue to $440 million to $445 million, ARR to $1.992 billion to $1.997 billion, and non-GAAP operating income to about $100 million. Full-year revenue guidance is $1.789 billion to $1.794 billion, ARR guidance is $2.065 billion to $2.070 billion, and non-GAAP operating income guidance is about $445 million.

The counterargument is carried by the same release. Q3 midpoint growth is about 8%, below Q2's 13%. Net new ARR was $37 million, and the full-year ARR target requires materially stronger second-half additions. The company also separated the COO and CFO roles, assigning sales, demand generation, and delivery execution to the COO during the slowdown.

Why This Can Move More Than 5% Soon

The September 4 session ranged from $14.77 to $17.19 and closed at $15.19 on 104.58 million shares. That confirms a large repricing regime and enough event sensitivity for another move above 5%. It does not establish direction or downside protection.

The next move depends on whether Q3 converts the guided revenue, ARR, and margin path. The cheapest earlier tests are customer additions, large-deal commentary, net new ARR, and any filed cash-flow or repurchase evidence.

10/5 Asymmetry Gate

The holding window is the first regular session after the holiday through December 15, 2026, or the first earlier Q3 filing. Targets use price-to-guided-revenue scenarios because the current provider denominator, September quote, and July balance sheet are not aligned enough for a precise enterprise-value bridge.

Measure	Reference-only result	Interpretation
Reference price	$15.19	September 4 regular-session context
Base target	$17.50	+15.21%
Bottom target	$12.50	-17.71%
Gross reward to adverse risk	0.86:1	Fails 2:1
Probability-weighted target	$17.13	+12.74% before costs
Measurement basis	Reference-only	`entry.price` is null
Status	Reject	No trade

The base move clears 10%, but the adverse path exceeds 5% and the ratio fails before costs.

What Should Surprise the Reader

UiPath achieved GAAP operating profit while revenue and ARR remained double-digit growers. The selloff is therefore not evidence of a broken business.

It is evidence that the market no longer rewards backward-looking profit improvement without forward acceleration. A 109% retention rate and $37 million of net new ARR leave limited room for execution error against the full-year ARR target.

The Setup

UiPath sells automation, orchestration, testing, and agent-governance software. The long thesis is that enterprises still need deterministic execution around AI agents and that operating discipline converts moderate growth into durable cash and profit.

The counterparty thesis is that generative AI lowers the cost of creating automations, growth slows toward single digits, and profitability comes partly from spending discipline rather than renewed product demand.

The Market Price

Field	Observation	Timestamp	Source and limitation
Price	$15.19	2026-09-04 23:57:55Z	Finance-feed regular-session context
Change	-$3.04, -16.68%	Same session	Finance feed
Open / high / low	$16.71 / $17.19 / $14.77	Same session	Finance feed
Volume	104,579,701 shares	Same session	Event-day volume; current depth unavailable
Provider market cap	$8.02B	Same observation	Provider field; current filed denominator not reconciled

The stock closed 2.84% above the intraday low. Price acceptance remains unresolved.

The Mispricing

Verified fact: Q2 revenue grew 13%, ARR grew 12%, and GAAP operating income improved to $32 million from a loss a year earlier. UiPath Q2 results

Verified fact: Q2 operating cash flow and adjusted free cash flow were each $31 million, below the $42 million and $45 million reported a year earlier.

Verified fact: Cash, cash equivalents, and marketable securities were $1.405 billion at July 31, down from $1.690 billion at January 31.

High-confidence inference: The market is discounting weaker forward ARR and revenue additions rather than disputing the current profit turn.

Unknown: Q3 large-deal pipeline, AI product contribution, customer acquisition cost, current denominator, current repurchase state, and whether lower stock compensation persists without retention costs.

The Positioning

The 104.58 million-share event tape shows intense turnover but does not identify forced sellers. The release's share tables and historical repurchase activity provide denominator context, but no current issuer purchase was verified for the event window.

Live short interest, borrow, options, dealer exposure, fund flows, and holder changes are unavailable. Positioning score: 2/5.

The Catalyst

Step	State	Timing	Observable test	Failure mode
Q3 revenue guide	Announced	Quarter ending Oct. 31	Verify $440M to $445M revenue and mix	Growth falls below the roughly 8% midpoint path
Q3 ARR guide	Announced	Oct. 31	Verify $1.992B to $1.997B ARR and net new ARR	Additions remain too weak for full-year target
Margin conversion	Announced	Q3 report	Reconcile GAAP profit, SBC, restructuring, and cash	Non-GAAP profit does not convert into operating cash
Leadership execution	In progress	Q3 and Q4	Test sales, demand generation, delivery, and CFO continuity	Reorganization signals execution strain
Price acceptance	Unobserved	First sessions and Q3 result	Verify spread, depth, venue, volume quality, and exit liquidity	Rebound fails or gap risk persists

The Payoff

The provider market cap of $8.02 billion and price of $15.19 imply roughly 528 million current shares, but that is a provider-derived denominator rather than a filed count. The target map therefore uses price-to-guided-revenue shorthand.

Top:    about 6.2x FY27 guided revenue on the provider denominator = $21.00
Base:   about 5.2x FY27 guided revenue on the provider denominator = $17.50
Bottom: about 3.7x FY27 guided revenue on the provider denominator = $12.50

The top requires ARR reacceleration and durable GAAP cash conversion. The base requires guidance delivery and multiple stabilization. The bottom assumes single-digit growth persists, AI weakens differentiation, and the multiple compresses further.

At 4.5x guided revenue, the price is about $15.25, nearly the current reference. A 10% revenue-guide cut combined with the base 5.2x multiple produces about $15.75, erasing most of the base upside.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	25%	$21.00	+38.25%	Through Dec. 15	ARR reaccelerates, Q3 guide beats, GAAP profit and cash persist	Medium-low
Base Case	50%	$17.50	+15.21%	Through Dec. 15	Guide holds, retention stabilizes, multiple recovers modestly	Medium
Bottom Case	25%	$12.50	-17.71%	Through Dec. 15	Single-digit growth persists, ARR disappoints, multiple compresses	Medium
Invalidation	n/a	Q3 filing breaks ARR and cash path	Thesis broken, not a stop	Any time	Revenue, ARR, retention, profit, or cash falls below the modeled path	High when filed

Probability rationale: The base receives 50% because Q2 beat and the full-year guide support continuity, but Q3 deceleration is explicit. Top and bottom each receive 25% because both renewed AI demand and further multiple compression are credible. These are analyst estimates, not observed frequencies.

Probability-weighted expected value: $17.125, rounded to $17.13, or +12.74% before costs. Current market level and timestamp: $15.19 at 2026-09-04 23:57:55Z. Primary instrument: PATH Class A common stock, NYSE. 10/5 favorable base move: +15.21% reference-only. 10/5 credible adverse move: -17.71% reference-only. Gross reward to adverse risk: 0.86:1. 10/5 measurement basis: Reference-only. 10/5 status: Reject. Confidence: Medium on reported results; low to medium on current valuation and future ARR acceleration.

The Kill Shot

The strongest counterparty view is that UiPath's profit improvement is already visible and the new information is a forward slowdown. Q3 midpoint revenue growth near 8%, a 109% retention rate, and only $37 million of net new ARR do not justify a premium automation multiple when general-purpose AI can lower workflow-building costs.

The load-bearing assumption is that customers need UiPath's governance and orchestration enough to reaccelerate ARR. If AI expands usage but reduces per-workflow pricing or sales cycles remain long, the business can stay profitable while the equity multiple keeps falling.

What Could Go Wrong

Q3 revenue and ARR can miss the guided ranges.
Net new ARR can remain below the pace required by the full-year target.
AI can increase automation demand while commoditizing parts of UiPath's product layer.
GAAP profit can remain positive while operating cash flow stays below the prior year.
Leadership changes can improve accountability or expose sales-execution strain.
Cash has declined and the current repurchase and denominator bridge is incomplete.
The event-day range and gap exceed the Desk's adverse hurdle.
Current spread, depth, venue, and exit liquidity are unverified.

What Would Prove This Wrong

The bear view weakens if Q3 revenue exceeds $445 million, ARR exceeds $1.997 billion, net new ARR reaccelerates, retention improves, and GAAP operating income converts into stronger operating cash without a denominator surprise.

The rebound thesis fails if Q3 growth falls below guide, full-year ARR is cut, retention weakens, SBC or restructuring reverses profit quality, or regular-session price acceptance remains disorderly.

Risk Audit

Risk	Why it matters	Control
Growth reset	Q3 guide implies slower growth	Require revenue, ARR, net new ARR, and retention together
AI competition	Demand growth may not equal pricing power	Verify paid product contribution and customer expansion
Cash quality	Profit improved while quarterly cash fell year over year	Reconcile CFO, capex, payroll taxes, restructuring, and deferred revenue
Denominator	Provider and filed shares are not aligned	Use price-only targets until current shares and repurchases reconcile
Event path	Friday's range exceeded 15%	No stop-as-protection or market order
Execution	Weekend research has no current book	Require fresh spread, depth, venue, volume, and exit evidence

Best Trade Strategy

No trade now. Keep entry.price null and execution.can_execute false. A future unlevered common-stock expression requires Q3 guide conversion, ARR reacceleration, cash and denominator reconciliation, and a fresh regular-session market-structure audit that supports a new 10/5 map. Options, leverage, margin, market orders, and price-floor logic are prohibited.

Sources

UiPath fiscal Q2 2027 results, September 3, 2026.
UiPath Q2 SEC earnings exhibit, September 3, 2026.
UiPath quarterly results archive, accessed September 6, 2026.
UiPath September 4 market reaction and forward-growth context, September 4, 2026; used for consensus mapping, not primary financial facts.

Research Quality Scorecard

Criterion	Score	Evidence
Market disagreement	5/5	16.7% selloff against reported growth and GAAP profit
Evidence base	4/5	Primary release and SEC exhibit; full 10-Q and current denominator pending
Positioning and flows	2/5	Event turnover is visible; direct positioning is not
Catalyst path	4/5	Q3 guide and filing are observable; date is not confirmed
Payoff architecture	4/5	Transparent revenue-multiple map and sensitivity, reference-only
Invalidation discipline	5/5	ARR, revenue, retention, cash, leadership, and tape tests are explicit
Differentiated insight	4/5	Profitability and multiple compression can coexist
Client value	5/5	Separates an operating beat from a safe rebound
Total	33/40	Substantive no-trade research; economics require Reject

Bottom Line

UiPath's Q2 profit turn is real. The market is pricing the harder question: whether ARR can reaccelerate as Q3 revenue growth slows toward 8%. The base rebound exceeds 10%, but a 17.7% credible adverse path and 0.86:1 reward-to-risk ratio fail the Desk's hurdle. Reject the long until Q3 growth, cash conversion, denominator, and regular-session execution evidence improve.

AI Illustration Prompt

Create an institutional editorial illustration of an enterprise automation control room. A disciplined green profit gauge has turned positive, while an ARR speedometer ahead is decelerating from double digits toward single digits. Show AI agents, software robots, and human operators connected through a governed orchestration rail, with a wide volatile price chart beneath them. Use graphite, cool white, muted teal, and restrained amber, avoid sci-fi excess, include precise ledger details, and add a subtle readable “The Mispricing Desk” watermark in the lower right.